Biogen "announced the outcome of the FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. On the question, "Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?" the Committee voted unanimously yes (9 yes to 0 no), for consideration of a potential accelerated approval. On the second question, "Does the clinical data from the placebo-controlled study and available long-term extension study results, with additional supporting results from the effects on relevant biomarkers (i.e., changes in plasma NfL concentration and/or reductions in SOD1), provide substantial evidence of the effectiveness of tofersen in the treatment of patients with SOD1-ALS?" the Committee voted 3 (yes), 5 (no) and 1 (abstain), for consideration of a potential traditional approval. Additionally, the committee discussed both of these topics and reached consensus that the benefit-risk profile was favorable based on the review of the totality of data for tofersen in people with SOD1-ALS."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
- FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
- Inozyme appoints Matthew Winton as COO
- FDA briefing docs suggest FDA in favor of Biogen’s tofersen, says BofA
- FDA posts briefing document for advisors’ review of Biogen’s ALS drug
